Product information and disease description Place of product in therapy Approaches to treatment Current treatment options and standard of care

Bispecific Anti-VEGF and angiopoietin-2 antibodies

5 evidence topics · 2 sources

Faricimab: mechanism and approval

“Faricimab-svoa, a humanized bispecific monoclonal antibody for intravitreal use that acts through dual inhibition of both angiopoietin-2 and VEGF-A, was approved by the FDA for the treatment of patients with neovascular AMD.” (opens the source at this quote in a new tab)

Faricimab: TENAYA and LUCERNE dosing intervals and injection counts

“Approximately 80% of eyes could be dosed every 12 weeks or more, and 45% could be dosed every 16 weeks in year 1 and increased to 63% in year 2.” (opens the source at this quote in a new tab)
“Through year 2, the median number of injections in the faricimab group was 10, compared with 15 for aflibercept.” (opens the source at this quote in a new tab)
“There were no new safety signals, and adverse events were comparable to aflibercept 2 mg.” (opens the source at this quote in a new tab)

Faricimab: intraocular inflammation and retinal vasculitis reports

“Recently, case reports of intraocular inflammation (excluding endophthalmitis) with faricimab were as high as 2% and retinal vasculitis with or without occlusion were 0.17 per 10,000 injections (vasculitis) and 0.06 per 10,000 for occlusive vasculitis.” (opens the source at this quote in a new tab)

Faricimab: dosing interval distribution at week 48 in TENAYA and LUCERNE with participant counts

“At week 48, approximately 80% of faricimab-treated patients in both TENAYA and LUCERNE were on 12-week or 16-week dosing intervals, with 107 (34·0%) patients in TENAYA and 104 (32·9%) patients in LUCERNE on extended dosing regimens of every 12 weeks, and 144 (45·7%) patients in TENAYA and 142 (44·9%) patients in LUCERNE on 16-week dosing” (opens the source at this quote in a new tab)
“More than 95% of patients in the faricimab group in both studies avoided losing 15 letters or more of vision from baseline at primary endpoint visits” (opens the source at this quote in a new tab)

Faricimab and aflibercept: intraocular inflammation and endophthalmitis in TENAYA and LUCERNE

“In TENAYA and LUCERNE, at week 48, rates of intraocular inflammation were low and on average reported in 2·0% of patients receiving faricimab and 1·2% of patients receiving aflibercept” (opens the source at this quote in a new tab)
“Two intraocular inflammation events (one uveitis in TENAYA, one vitritis in LUCERNE) in the faricimab group and one uveitis event (LUCERNE) in the aflibercept group led to a decrease of 30 or more letters in visual acuity score lasting more than 1 h” (opens the source at this quote in a new tab)
“There was one report of endophthalmitis in the aflibercept group of LUCERNE, which was culture negative.” (opens the source at this quote in a new tab)